Research progress of dydrogesterone in the treatment of endometriosis
- PMID: 38430648
- DOI: 10.1016/j.ejogrb.2024.02.034
Research progress of dydrogesterone in the treatment of endometriosis
Abstract
Endometriosis is a common gynecological disease among women of reproductive age. It is a chronic estrogen and progestin related inflammatory disease. At present, the main treatments for endometriosis are drug therapy and surgery. In drug therapy, progesterone is listed as the first-line recommendation in multinational guidelines. Dydrogesterone, as an oral reversal progesterone, can slow down the metabolism of progesterone, inhibit angiogenesis and extracellular matrix degradation to inhibit the proliferation of the ectopic endometrium, induce the atrophy of the ectopic endometrium through the pro-apoptotic pathway, and treat endometriosis through multiple mechanisms of regulating inflammatory factors to reduce inflammation. Clinically, dydrogesterone treatment of endometriosis can relieve patients' symptoms, promote fertility, be used in combination, and is safe. This article will review the mechanism and clinical application of dydrogesterone in the treatment of endometriosis.
Keywords: Clinical research; Dydrogesterone; Endometriosis; Mechanism.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure.Hum Reprod Update. 2020 Jun 18;26(4):565-585. doi: 10.1093/humupd/dmaa009. Hum Reprod Update. 2020. PMID: 32412587 Free PMC article.
-
Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice.Reprod Biol Endocrinol. 2018 Apr 3;16(1):32. doi: 10.1186/s12958-018-0347-9. Reprod Biol Endocrinol. 2018. PMID: 29615065 Free PMC article.
-
Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis.Arch Gynecol Obstet. 2021 Jul;304(1):231-252. doi: 10.1007/s00404-020-05900-z. Epub 2021 Jan 4. Arch Gynecol Obstet. 2021. PMID: 33398505 Free PMC article.
-
Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line.Chem Biol Interact. 2013 Feb 25;202(1-3):218-25. doi: 10.1016/j.cbi.2012.10.028. Epub 2012 Nov 23. Chem Biol Interact. 2013. PMID: 23183084
-
Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium.Maturitas. 2009 Dec;65 Suppl 1:S3-11. doi: 10.1016/j.maturitas.2009.10.011. Epub 2009 Dec 6. Maturitas. 2009. PMID: 19969432 Review.
Cited by
-
Development and functional evaluation of recombinant type III collagen intrauterine implant gel.Regen Biomater. 2025 Mar 17;12:rbaf013. doi: 10.1093/rb/rbaf013. eCollection 2025. Regen Biomater. 2025. PMID: 40196171 Free PMC article.
-
Real-World Evidence of Dydrogesterone 20 mg and 30 mg SR Usage in Pregnancy.Cureus. 2024 Oct 21;16(10):e72016. doi: 10.7759/cureus.72016. eCollection 2024 Oct. Cureus. 2024. PMID: 39569237 Free PMC article.
-
A novel fertility-sparing nanocomposite for endometriosis treatment via oxidative stress and inflammation alleviation.Mater Today Bio. 2025 Jul 1;33:102041. doi: 10.1016/j.mtbio.2025.102041. eCollection 2025 Aug. Mater Today Bio. 2025. PMID: 40677401 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical